VictorManuelVillalobosMDPhD

Executive Medical Director

Dr. Villalobos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1665 Aurora Ct
ACP room 5329 Mail stop F704
Aurora, CO 80045
Phone+1 720-848-0467

Fax+1 650-736-8003

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2010 - 2013
Washington University in St. Louis School of MedicineClass of 2008

PubMed

17 citations
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, Victor Moreno, Solange Peters
Lung Cancer. 2020-10-10
332 citations
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Branimir I. Sikic, Nehal Lakhani, Amita Patnaik, Sumit A. Shah, Sreenivasa R Chandana
Journal of Clinical Oncology. 2016-05-20
254 citations
The management of desmoid tumours : A joint global consensus-based guideline approach for adult and paediatric patients
Ben Alman, Steven Attia, Christina Baumgarten, Charlotte Benson, Jean-Yves Blay
European Journal of Cancer. 2020-03-01

Lectures

Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018